Production (Stage)
CannaPharmaRX, Inc.
CPMD
$0.004
$0.000.00%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1,199.61% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,199.61% | -- | -- | -- | -- |
| Cost of Revenue | 12.88% | 3,245.73% | -- | -- | -- |
| Gross Profit | 29.85% | -2,510.67% | -- | -- | -- |
| SG&A Expenses | -49.92% | 79.83% | -76.00% | -65.53% | -49.03% |
| Depreciation & Amortization | -- | 9.16% | -- | -13.24% | -68.66% |
| Other Operating Expenses | -- | -49.00% | -- | -- | -- |
| Total Operating Expenses | -8.41% | 383.80% | 21.36% | -61.18% | 52.03% |
| Operating Income | 37.56% | -315.46% | 25.41% | 61.18% | -48.45% |
| Income Before Tax | 94.11% | -149.58% | 133.38% | 385.29% | -729.36% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 94.11% | -149.58% | 133.38% | 385.29% | -729.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 94.11% | -149.58% | 133.38% | 385.29% | -729.36% |
| EBIT | 37.56% | -315.46% | 25.41% | 61.18% | -48.45% |
| EBITDA | 36.18% | -275.09% | 4.79% | 68.17% | -46.42% |
| EPS Basic | 97.01% | -126.54% | 115.79% | 228.57% | -595.83% |
| Normalized Basic EPS | 96.83% | -975.00% | 116.67% | 273.68% | -1,005.00% |
| EPS Diluted | 97.01% | -126.54% | 115.79% | 228.57% | -595.83% |
| Normalized Diluted EPS | 96.83% | -975.00% | 116.67% | 273.68% | -1,005.00% |
| Average Basic Shares Outstanding | 89.01% | 85.27% | 124.50% | 119.58% | 19.68% |
| Average Diluted Shares Outstanding | 89.01% | 85.27% | 124.50% | 119.58% | 19.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |